Lack of effect of subject posture on intravenous midazolam clearance: Implications for hepatic cytochrome P450 3A phenotyping

British Journal of Clinical Pharmacology

Volumn 67, Issue 3, 2009, Pages 374-375

  Ma, Joseph D ^a,b   Nafziger, Anne N ^b,d   Mylott, William ^c   Haughey, David B ^c   Rocci Jr , Mario L ^c   Bertino Jr , Joseph S ^b,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b BASSETT RESEARCH INSTITUTE   (United States)

^c ICON PLC   (United Kingdom)

^d BERTINO CONSULTING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM;

ADULT; BODY POSTURE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; LETTER; LIVER BLOOD FLOW; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SAMPLE SIZE;

CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; POSTURE; REGIONAL BLOOD FLOW;

EID: 62949175363     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03361.x     Document Type: Letter

References (12)

1. Ma J, Nafziger A, Rhodes G, Liu S, Gartung A, Bertino J. The effect of oral pleconaril on hepatic cytochrome p450 3a activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol 2006 46 : 103 8.
2. Rogers J, Rocci M, Haughey D, Bertino J. An evaluation of the suitability of IV midazolam as an in vivo marker for hepatic CYP3A activity. Clin Pharmacol Ther 2003 73 : 153 8.
3. Wilkinson G, Shand D. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975 18 : 377 90.
4. Queckenberg C, Fuhr U. Influence of posture on pharmacokinetics. Eur J Clin Pharmacol 2008 Oct 21 [Epub ahead of print U, Ziegler G. Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther 1982 32 : 107 12.
5. Ma J, Nafziger A, Mylott W, Haughey D, Rocci M, Bertino J. Quantitative assessment of hepatic blood flow using intravenous indocyanine green. Eur J Clin Pharmacol 2008 64 : 1133 4.
6. Fayer J, Zannikos P, Stevens J, Luo Y, Sidhu R, Kirkesseli S. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. J Clin Pharmacol 2001 41 : 305 16.
7. Hotz M, Ritz R, Linder L, Scollo-Lavizzari G, Haefeli W. Auditory and electroencephalographic effects of midazolam and a-hydroxy-midazolam in healthy subjects. Br J Clin Pharmacol 2000 49 : 72 9.
8. Klotz U, Reimann I. Chronopharmacokinetic study with prolonged infusion of midazolam. Clin Pharmackinetics 1984 9 : 469 74.
9. Wandel C, Witte J, Hall J, Stein C, Wood A, Wilkinson G. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5′-promoter regional polymorphism. Clin Pharmacol Ther 2000 68 : 82 91.
10. Daneshmend T, Jackson L, Roberts C. Physiological and pharmacological variability in estimated hepatic blood flow in man. Br J Clin Pharmacol 1981 11 : 491 6.
11. Grasela D, Rocci M, Rotmensch H, Vlasses P. Lack of effect of multiple does of cimetidine on estimated hepatic blood flow. Biopharm Drug Dispos 1987 8 : 63 72.
12. Svensson C, Edwards D, Mauriello P, Barde S, Foster A, Lanc R, Middleton E, Lalka D. Effect of food on hepatic blood flow: implications in the 'food effect' phenomenon. Clin Pharmacol Ther 1983 34 : 316 23.